Jan Aldershvile, Odd Dietrichson, Peter SkinhøJ, Peter Kryger, Lars R. Mathiesen, Per Christoffersen, Jens O. Nielsen, The Copenhagen Hepatitis Acuta Programme – 1 March 1982 – In order to evaluate the prognostic implications of the hepatitis B e system in patients with chronic persistent hepatitis (CPH), 53 consecutive patients were studied. Fourteen of 16 patients with HBsAg and HBeAg were followed from 12 to 120 months (mean, 38 months). Eleven of the 14 patients were persistently HBeAg positive and five of these developed chronic active hepatitis (CAH) or cirrhosis.

George Hamilton, Rose Chow Fung Phing, Ronald A. Hutton, Paresh Dandona, Kenneth E. F. Hobbs – 1 March 1982 – The effect of portal hypertension (induced by partial ligation) on the ability of the portal vein wall to produce prostacyclin (PGI2) was studied in rats over a period of 6 weeks. PGI2‐like activity measured by bioassay was shown to be significantly increased in portal vein segments during established hypertension when compared to control groups. As a collateral circulation developed with consequent fall in portal venous pressure, PGI2‐like activity decreased.

Hyman J. Zimmerman, Charles O. Abernathy, Lorinc Lukacs, Mildred Ezekiel – 1 March 1982 – Ticrynafen, a uricosuric diuretic agent which causes hepatocellular injury in man as an apparent idiosyncratic reaction, was found to impair the function of the isolated perfused rat liver. At concentrations in the perfusate equivalent to those produced in the blood of man by therapeutic doses, the drug led to a striking reduction in bile flow and sulfobromophthalein excretion and release of aspartate aminotransferase into the perfusate.

1 March 1982

John K. Boitnott – 1 March 1982

Nicholas F. Larusso, Louis J. Kost, Janet A. Carter, Steven S. Barham – 1 March 1982 – In these experiments, we tested two hypotheses: first, that Triton WR‐1339, a nonionic detergent which is sequestered in hepatocyte lysosomes, undergoes biliary excretion; and second, that Triton WR‐1339, which also alters serum lipid levels and modifies hepatic catabolism of lipoproteins, affects the biliary output of proteins and lipids.

Henry Gans, David Eberle – 1 March 1982

Rosemarie L. Fisher, Deborah W. Anderson, James L. Boyer, Kamal Ishak, Gerald Klatskin, John M. Lachin, M. James Phillips, The Steering Committee, The National Cooperative Gallstone Study Group – 1 March 1982 – A sample of 126 patients with cholelithiasis was treated with chenodeoxycholic acid (CDCA) (375 or 750 mg g.d.) for 2 years. Hepatotoxicity was assessed by sequential light (LM) and electron microscopic (EM) analysis of liver biopsies obtained before and after 9 and 24 months of therapy.

Patrice Vic, Bernard Saint‐Aubert, Cecile Astre, Philippe Bories, Andree Bonardet, Bernard Descomps, Claude Humeau, Henri Joyeux – 1 March 1982

1 March 1982